4D Molecular Therapeutics: Novo reports 5.4% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
4D Molecular Therapeutics, Inc. (FDMT) is the issuer whose shares Novo Holdings A/S reported beneficially owning: 3,000,000 common shares, or 5.4% of the class, as of September 30, 2026. Novo Holdings reported sole voting and dispositive power over all 3,000,000 shares, with no shared voting or dispositive power.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power technical
Sole Dispositive Power technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.